Best Practices for Managing Tyrosine Kinase Inhibitor-Related Adverse Events

EP. 1: Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs

October 21st 2022

Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.

EP. 2: Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs

October 21st 2022

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

EP. 3: Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs

November 3rd 2022

Zofia Piotrowska, MD, discusses the management of paronychia associated with EGFR TKIs.

EP. 4: Best Practices for Managing EGFR Tyrosine Kinase Inhibitor–Related Adverse Events

November 28th 2022

An overview of EGFR tyrosine kinase inhibitors (TKIs), common adverse events with EGFR TKI therapy and management strategies for them, and additional notable toxicities with EGFR TKIs.

EP. 5: Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs

November 28th 2022

Christine Lovly, MD, PhD, Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, and Linda Ahn discuss how to approach treatment-related adverse effects of the skin and mouth associated with the use of EGFR TKIs.

EP. 6: Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIs

November 29th 2022

Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.

EP. 7: Experts Discuss Common AEs With EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects with EGFR TKIs.

EP. 8: Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the safety profile of mobocertinib in EGFR exon 20 insertion mutation–positive advanced non–small cell lung cancer.

EP. 9: Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

November 29th 2022

Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

EP. 10: Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.

EP. 11: Experts on the Management of Diarrhea Associated With EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.